How Have the Numbers Shaped Up for Enveric Biosciences (NASDAQ:ENVB)

Earnings results for Enveric Biosciences (NASDAQ:ENVB)

Enveric Biosciences, Inc. is estimated to report earnings on 08/13/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-1.92.

Enveric Biosciences last posted its earnings data on May 18th, 2021. The reported ($0.20) earnings per share for the quarter. Enveric Biosciences has generated ($1.19) earnings per share over the last year. Earnings for Enveric Biosciences are expected to grow in the coming year, from ($0.60) to ($0.37) per share. Enveric Biosciences has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Friday, August 13th, 2021 based off prior year’s report dates.

Analyst Opinion on Enveric Biosciences (NASDAQ:ENVB)

2 Wall Street analysts have issued ratings and price targets for Enveric Biosciences in the last 12 months. Their average twelve-month price target is $6.50, predicting that the stock has a possible upside of 238.54%. The high price target for ENVB is $7.00 and the low price target for ENVB is $6.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of “Buy.”

Enveric Biosciences has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $6.50, Enveric Biosciences has a forecasted upside of 238.5% from its current price of $1.92. Enveric Biosciences has only been the subject of 2 research reports in the past 90 days.

Dividend Strength: Enveric Biosciences (NASDAQ:ENVB)

Enveric Biosciences does not currently pay a dividend. Enveric Biosciences does not have a long track record of dividend growth.

Insiders buying/selling: Enveric Biosciences (NASDAQ:ENVB)

In the past three months, Enveric Biosciences insiders have not sold or bought any company stock. Only 1.04% of the stock of Enveric Biosciences is held by insiders. Only 5.35% of the stock of Enveric Biosciences is held by institutions.

Earnings and Valuation of Enveric Biosciences (NASDAQ:ENVB

Earnings for Enveric Biosciences are expected to grow in the coming year, from ($0.60) to ($0.37) per share. The P/E ratio of Enveric Biosciences is -1.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Enveric Biosciences is -1.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Enveric Biosciences has a P/B Ratio of 8.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

More latest stories: here